Evidence map›Paper›PMID 28246586›Full record

ArticleWorld journal of clinical oncology2017

Anders Lorentzen, Cathy Mitchelmore

Open access · hybridAbstract read
In one paragraph

Article in World journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Anders LorentzenAnders Lorentzen, Cathy Mitchelmore, Eucaryotic Cell Biology, Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark.
Cathy MitchelmoreAnders Lorentzen, Cathy Mitchelmore, Eucaryotic Cell Biology, Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark.
Creative Research Enterprises (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate if the down-regulation of

methodsThe following were investigated in the human colorectal cancer cell lines DLD-1, LoVo and SW-480: NDRG2 mRNA expression levels using quantitative reverse transcription-polymerase chain reaction (qRT-PCR); interaction of the MYC gene-regulatory protein with the

resultsAs expected, NDRG2 mRNA levels were low in the three colorectal cancer cell lines, compared to normal colon. Endogenous MYC protein interacted with the

conclusionOur study suggests that the reduction in

Indexed as

Allelic lossColorectal carcinomaCopy numberGene amplificationMYCN-myc downstream-regulated gene 2Tumor suppressor

Identifiers

PMID28246586
PMCPMC5309715
OpenAlexW2587329882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.